San Francisco, Cali. – January 9, 2013 – Conformis, Inc., a privately held medical device company pioneering patient-specific orthopedic implants for the treatment of osteoarthritis, announced today its participation in the JP Morgan Annual Healthcare Conference.

Dr. Philipp Lang, CEO of Conformis, will provide an overview of the company beginning at 8:00 am PST (11:00 am EST). Conformis is the leading provider of patient-specific knee replacement implants and instruments, and currently the fastest growing company in orthopedics.

In October 2012, Conformis announced the commercial launch of its iTotal^® G2, the only patient-specific total knee replacement implant system available on the market. The iTotal allows Conformis to address the largest segment of the knee replacement market, currently a $6 billion dollar category. Conformis also recently moved its corporate office to a substantially larger facility in Massachusetts to support the recent and expected forward growth of the company.

About Conformis, Inc. 
Conformis, Inc. is a privately-held medical device company that develops and commercializes patient-specific implants and instrumentation to address all stages of osteoarthritis, the most common reason for knee replacement surgery. With more than 350 patents and patent applications spanning knee, hip, shoulder, spine and small joints, Conformis offers a personalized approach over traditional orthopedic implants with their iUni^® G2, iDuo^® G2 and iTotal^® G2. All devices have been cleared by the US Food and Drug Administration for marketing in the US. In 2009, Conformis was named a winner of the Medical Design Excellence Awards for the iUni^® and iDuo^® resurfacing implants and in 2011, received a Medical Design Excellence Award and an American Technology Award for Innovation for the iTotal^® CR Knee Replacement System. Follow @Conformis and become a fan on Facebook.